MyMD Pharmaceuticals, Inc. MYMD stock price (” MyMD” or “the Firm”), a clinical stage pharmaceutical company devoted to prolonging healthy life-span, today announced that the very first client has been enrolled in the Business’s Phase 2 medical trial of lead prospect MYMD-1, a dental immune regulator medicine, as a treatment for postponing aging and increasing healthy lifespan.
The main endpoint for the Phase 2 double-blind, placebo-controlled clinical test is to attain a reduction in the circulating levels of (TNF-α), growth death element receptor I (TNFRI) and IL-6. TNF-α and IL-6 are the proteins in the body that trigger inflammation as well as assist activate the procedure of aging. The secondary actions of the trial will be the safety, tolerability, and also pharmacokinetics in this population of clients.
” In a Stage 1 scientific test of MYMD-1, we showed the medicine’s statistically substantial efficiency in decreasing levels of TNF-α, a key player in triggering pathological aging, in the blood. The FDA has actually approved TNF-α decrease as the primary endpoint for our Stage 2 study, which our company believe placements us well for a successful Phase 2 end result,” claimed Chris Chapman, M.D., President, Supervisor and Chief Medical Policeman of MyMD. “The initiation of person registration in this research study developments our objective to reduce the aging process, stop loss of muscle mass cells in aging, limitation frailty, and also expand healthy lifespan.”
MyMD has stated that there are no FDA-approved medications for dealing with aging disorders as well as expanding healthy and balanced lifespan human beings, a market expected to be a minimum of $600 billion by 20251 according to a significant financial investment financial institution. TNF-α blockers are the most prescribed medicines by income, a worldwide market of about $40 billion per year,2 as well as, according to Nature Aging journal,3 a downturn in aging that would boost life span by one year deserves $38 trillion as well as by one decade deserves $367 trillion.
In addition to aging, MYMD-1’s unique action in regulating the immune system and treating persistent swelling is being developed for the therapy of autoimmune condition, including rheumatoid arthritis (RA), several sclerosis (MS), diabetes mellitus, as well as inflammatory bowel illness.
” We plan to begin creating procedures for a Stage 2 pilot research of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman kept in mind. “The climbing occurrence of rheumatoid arthritis and also various other autoimmune and inflammatory conditions are driving demand for TNF preventions like MYMD-1, as well as we believe our by mouth administered medication with really low poisoning would be turbulent to the $60 billion market for RA if authorized by the FDA for this sign.”
Rheumatoid arthritis affects about 40 million people around the world.4.
Originally established for autoimmune conditions, MYMD-1’s primary purpose is to slow the aging process, stop sarcopenia and frailty, as well as prolong healthy and balanced lifespan. Because it can go across the blood-brain barrier and also gain access to the main nerve system (CNS), MYMD-1 is also positioned to be a possible therapy for brain-related problems. Its device of action and efficacy in conditions including several sclerosis (MS) and also thyroiditis have been researched through cooperations with several scholastic establishments. MYMD-1 is also showing guarantee in pre-clinical studies as a potential therapy for post- COVID-19 problems and also as an anti-fibrotic as well as anti-proliferation therapeutic.
MYMD-1 has actually shown performance in pre-clinical studies in managing the body immune system by doing as a selective prevention of tumor death factor-alpha (TNF-α), a driver of persistent swelling. Unlike various other therapies, MYMD-1 has been displayed in these pre-clinical research studies to precisely block TNF-α when it comes to be overactivated in autoimmune diseases as well as cytokine tornados, however not block it from doing its typical task of being a very first -responder to any type of routine sort of modest infection. MYMD-1’s ease of dental dosing is another differentiator compared to currently offered TNF-α blockers, all of which need shipment by shot or mixture. No authorized TNF prevention has actually ever before been dosed by mouth. In addition, the medicine is not immunosuppressive and has not been shown to trigger the major negative effects usual with standard therapies that deal with inflammation.
Concerning MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a medical phase pharmaceutical company devoted to prolonging healthy life expectancy, is concentrated on establishing two unique healing platforms that deal with the sources of illness as opposed to only addressing the signs. MYMD-1 is a medication platform based on a clinical stage tiny molecule that controls the immune system to regulate TNF-α, which drives chronic swelling, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to postpone aging, rise durability, and deal with autoimmune conditions and also COVID-19- linked clinical depression. The Firm’s 2nd medication system, Supera-CBD, is being created to treat chronic pain, addiction as well as epilepsy. Supera-CBD is an unique artificial by-product of cannabidiol (CBD) and is being developed to resolve and surpass the rapidly expanding CBD market, that includes both FDA approved medications as well as CBD items not presently controlled as medications. To learn more, go to www.mymd.com.